Mdxhealth has unveiled new findings from Oxford’s ProMPT Study, which show that the Genomic Prostate Score (GPS) test can predict adverse outcomes for prostate cancer patients. Presented at EAU 2026, this research highlights the test’s broad relevance across multiple treatment approaches.